Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 4/2014

01.04.2014 | Original Article

Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry

verfasst von: Joyce C. Mhlanga, Daniel Durand, Hua-Ling Tsai, Christine M. Durand, Jeffrey P. Leal, Hao Wang, Richard Moore, Richard L. Wahl

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine the diagnostic accuracy of a semiautomated 18F-FDG PET/CT measurement of total lesion glycolysis (TLG), maximum and peak standardized uptake value at lean body mass (SUL-Max and SUL-Peak), qualitative estimates of left/right nodal symmetry and FDG uptake for differentiating lymphoma from reactive adenopathy in HIV-infected patients.

Methods

We retrospectively analyzed 41 whole-body 18F-FDG PET/CT studies performed in HIV-infected patients for clinical reasons. The study received institutional review board approval. Of the 41 patients, 19 had biopsy-proven untreated lymphoma, and 22 with reactive adenopathy without malignancy on follow-up were used as controls. Nodal and extranodal visual qualitative metabolic scores, SUL-Max, SUL-Peak, CT nodal size, and PERCIST 1.0 threshold-based TLG and metabolic tumor volume (MTV) were determined. The qualitative intensity of nodal involvement and symmetry of uptake were compared using receiver operator curve (ROC) analysis. HIV plasma viral RNA measurements were also obtained.

Results

All of the quantitative PET metrics performed well in differentiating lymphoma from reactive adenopathy and performed better than qualitative visual intensity scores. The areas under the ROC curves (AUC) were significantly higher for TLG = 0.96, single SUL-Peak = 0.96, single SUL-Max = 0.97, and MTV = 0.96, compared to 0.67 for CT nodal size (p < 0.001). These PET metrics performed best in separating the two populations in aviremic patients, with AUCs of 1 (AUC 0.91 for CT nodal size). TLG, MTV, SUL-Peak and SUL-Max were more reliable markers among viremic individuals, with AUCs between 0.84 and 0.93, compared to other metrics. PET metrics were significantly correlated with plasma viral load in HIV-reactive adenopathy controls. Asymmetrical FDG uptake had an accuracy of 90.4 % for differentiating lymphoma from reactive adenopathy in HIV-infected patients.

Conclusion

Quantitative PET metabolic metrics as well as the qualitative assessment of symmetry of nodal uptake appear to be valuable tools for differentiating lymphoma from reactive adenopathy in HIV-infected patients using FDG PET. These parameters appear more robust in aviremic patients.
Literatur
1.
Zurück zum Zitat Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223–48.PubMedCrossRef Moir S, Chun TW, Fauci AS. Pathogenic mechanisms of HIV disease. Annu Rev Pathol. 2011;6:223–48.PubMedCrossRef
2.
Zurück zum Zitat Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805–9.PubMedCrossRef Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet. 1991;337:805–9.PubMedCrossRef
3.
Zurück zum Zitat Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14–9.PubMedCrossRef Bower M, Palmieri C, Dhillon T. AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy. Curr Opin Infect Dis. 2006;19:14–9.PubMedCrossRef
4.
Zurück zum Zitat Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.PubMedCentralPubMedCrossRef Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–62.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959–61.PubMedCrossRef Scharko AM, Perlman SB, Pyzalski RW, Graziano FM, Sosman J, Pauza CD. Whole-body positron emission tomography in patients with HIV-1 infection. Lancet. 2003;362:959–61.PubMedCrossRef
6.
Zurück zum Zitat Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25:536–46.PubMedCrossRef Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25:536–46.PubMedCrossRef
7.
Zurück zum Zitat Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005;25:1357–68.PubMedCrossRef Love C, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics. 2005;25:1357–68.PubMedCrossRef
8.
Zurück zum Zitat Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980–5.PubMedCrossRef Keidar Z, Gurman-Balbir A, Gaitini D, Israel O. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980–5.PubMedCrossRef
9.
Zurück zum Zitat Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. FDG-PET in fever of unknown origin. Semin Nucl Med. 2013;43:333–9.PubMedCrossRef Kouijzer IJ, Bleeker-Rovers CP, Oyen WJ. FDG-PET in fever of unknown origin. Semin Nucl Med. 2013;43:333–9.PubMedCrossRef
10.
Zurück zum Zitat Bental M, Deutsch C. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med. 1993;29:317–26.PubMedCrossRef Bental M, Deutsch C. Metabolic changes in activated T cells: an NMR study of human peripheral blood lymphocytes. Magn Reson Med. 1993;29:317–26.PubMedCrossRef
11.
Zurück zum Zitat Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985–9.PubMedCrossRef Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985–9.PubMedCrossRef
12.
Zurück zum Zitat Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25:571–8.PubMedCrossRef
13.
Zurück zum Zitat O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–83.PubMed O’Doherty MJ, Barrington SF, Campbell M, Lowe J, Bradbeer CS. PET scanning and the human immunodeficiency virus-positive patient. J Nucl Med. 1997;38:1575–83.PubMed
14.
Zurück zum Zitat Goudarzi B, Jacene HA, Wahl RL. Measuring the “unmeasurable”: assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010;17(9):1175–85.PubMedCrossRef Goudarzi B, Jacene HA, Wahl RL. Measuring the “unmeasurable”: assessment of bone marrow response to therapy using FDG-PET in patients with lymphoma. Acad Radiol. 2010;17(9):1175–85.PubMedCrossRef
15.
Zurück zum Zitat Lodge MA, Chaudhry MA, Udall DN, Wahl RL. Characterization of a perirectal artifact in 18F-FDG PET/CT. J Nucl Med. 2010;51(10):1501–6.PubMedCrossRef Lodge MA, Chaudhry MA, Udall DN, Wahl RL. Characterization of a perirectal artifact in 18F-FDG PET/CT. J Nucl Med. 2010;51(10):1501–6.PubMedCrossRef
16.
Zurück zum Zitat Liu Y. Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. AIDS Res Treat. 2012; 2012:764291.PubMedCentralPubMed Liu Y. Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. AIDS Res Treat. 2012; 2012:764291.PubMedCentralPubMed
17.
Zurück zum Zitat Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50.
18.
Zurück zum Zitat Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.PubMedCrossRef Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;285:1736–45.PubMedCrossRef
20.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.PubMedCrossRef
22.
Zurück zum Zitat Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477–82.PubMedCrossRef Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477–82.PubMedCrossRef
23.
Zurück zum Zitat Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet. 2003;362:945–50.PubMedCrossRef Iyengar S, Chin B, Margolick JB, Sabundayo BP, Schwartz DH. Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet. 2003;362:945–50.PubMedCrossRef
24.
Zurück zum Zitat Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430–8.PubMedCrossRef Lim ST, Karim R, Nathwani BN, Tulpule A, Espina B, Levine AM. AIDS-related Burkitt’s lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. J Clin Oncol. 2005;23:4430–8.PubMedCrossRef
25.
Zurück zum Zitat Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985–93.PubMedCrossRef Brust D, Polis M, Davey R, Hahn B, Bacharach S, Whatley M, et al. Fluorodeoxyglucose imaging in healthy subjects with HIV infection: impact of disease stage and therapy on pattern of nodal activation. AIDS. 2006;20:985–93.PubMedCrossRef
26.
Zurück zum Zitat Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003;17:673–96.PubMedCrossRef Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol Oncol Clin North Am. 2003;17:673–96.PubMedCrossRef
27.
Zurück zum Zitat Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33:610–4.PubMedCrossRef Goshen E, Davidson T, Avigdor A, Zwas TS, Levy I. PET/CT in the evaluation of lymphoma in patients with HIV-1 with suppressed viral loads. Clin Nucl Med. 2008;33:610–4.PubMedCrossRef
28.
Zurück zum Zitat Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640–7.PubMedCrossRef Lucignani G, Orunesu E, Cesari M, Marzo K, Pacei M, Bechi G, et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. Eur J Nucl Med Mol Imaging. 2009;36:640–7.PubMedCrossRef
29.
Zurück zum Zitat Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–8.PubMed Paquet N, Albert A, Foidart J, Hustinx R. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004;45:784–8.PubMed
Metadaten
Titel
Differentiation of HIV-associated lymphoma from HIV-associated reactive adenopathy using quantitative FDG PET and symmetry
verfasst von
Joyce C. Mhlanga
Daniel Durand
Hua-Ling Tsai
Christine M. Durand
Jeffrey P. Leal
Hao Wang
Richard Moore
Richard L. Wahl
Publikationsdatum
01.04.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 4/2014
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2671-9

Weitere Artikel der Ausgabe 4/2014

European Journal of Nuclear Medicine and Molecular Imaging 4/2014 Zur Ausgabe